Trails Edge Capital Partners, LP: XENON PHARMACEUTICALS INC (XENE): Quarterly 13F Position History
As of Q1 2026, Trails Edge Capital Partners, LP reported 440,000 shares of XENON PHARMACEUTICALS INC (XENE), worth $25.6M and representing 6.0% of its 13F equity book. Quarter-over-quarter share count change: 157,092 (-26.3%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 440,000Shares Held (Latest Filing)
- $25.6MReported Market Value (Latest Filing)
- 6.0%Portfolio Weight (% of 13F Equity Book)
- 157,092Quarter-over-Quarter Share Change
- -$1.2MQuarter-over-Quarter Value Change
- 597,092Peak Reported Shares (Historical)
Recent initiation: Trails Edge Capital Partners, LP first reported XENE on the Q4 2025 filing — fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 440,000 | 157,092 | -26.3% | $25.6M | 6.0% | $58.1 |
| Q4 2025 | 597,092 | — | — | $26.8M | 6.6% | $44.8 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Trails Edge Capital Partners, LP first disclose a XENE position in 13F-HR filings?
Trails Edge Capital Partners, LP first reported XENON PHARMACEUTICALS INC (XENE) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Trails Edge Capital Partners, LP's most recent quarter-over-quarter share-count change in XENE?
Between Q4 2025 and Q1 2026, Trails Edge Capital Partners, LP reduced its XENE position by 157,092 shares (-26.3%), leaving 440,000 shares at a market value of $25.6M.
Does the implied price-per-share represent Trails Edge Capital Partners, LP's cost basis in XENE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.